Which has preferable valuation and earnings, XENE or TYRA?

Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xenon Pharmaceuticals N/A N/A -$345.91M -$4.74 N/A Tyra Biosciences N/A N/A -$119.95M -$2.40 N/A

Is XENE or TYRA more profitable?

Xenon Pharmaceuticals' return on equity of -43.98% beat Tyra Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Xenon Pharmaceuticals N/A -43.98% -41.72% Tyra Biosciences N/A -46.39% -43.07%

Does the media refer more to XENE or TYRA?

In the previous week, Xenon Pharmaceuticals had 3 more articles in the media than Tyra Biosciences. MarketBeat recorded 4 mentions for Xenon Pharmaceuticals and 1 mentions for Tyra Biosciences. Xenon Pharmaceuticals' average media sentiment score of 1.24 beat Tyra Biosciences' score of 0.00 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tyra Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor KNSA or TYRA?

In the previous week, Kiniksa Pharmaceuticals International and Kiniksa Pharmaceuticals International both had 1 articles in the media. Kiniksa Pharmaceuticals International's average media sentiment score of 1.63 beat Tyra Biosciences' score of 0.00 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals International 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Tyra Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PTCT or TYRA?

In the previous week, PTC Therapeutics had 16 more articles in the media than Tyra Biosciences. MarketBeat recorded 17 mentions for PTC Therapeutics and 1 mentions for Tyra Biosciences. PTC Therapeutics' average media sentiment score of 0.70 beat Tyra Biosciences' score of 0.00 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tyra Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TYRA or LGND?

In the previous week, Ligand Pharmaceuticals had 3 more articles in the media than Tyra Biosciences. MarketBeat recorded 4 mentions for Ligand Pharmaceuticals and 1 mentions for Tyra Biosciences. Ligand Pharmaceuticals' average media sentiment score of 0.33 beat Tyra Biosciences' score of 0.00 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tyra Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ligand Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TYRA or TVTX?

In the previous week, Travere Therapeutics had 9 more articles in the media than Tyra Biosciences. MarketBeat recorded 10 mentions for Travere Therapeutics and 1 mentions for Tyra Biosciences. Travere Therapeutics' average media sentiment score of 1.14 beat Tyra Biosciences' score of 0.00 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tyra Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Travere Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tyra Biosciences (TYRA) Competitors

$26.26 +0.21 (+0.82%)

As of 02:42 PM Eastern

Compare

TYRA vs. XENE, KNSA, PTCT, LGND, and TVTX

Should you buy Tyra Biosciences stock or one of its competitors? Tyra Biosciences's main competitors and comparable companies include Xenon Pharmaceuticals (XENE), Kiniksa Pharmaceuticals International (KNSA), PTC Therapeutics (PTCT), Ligand Pharmaceuticals (LGND), and Travere Therapeutics (TVTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tyra Biosciences compare to Xenon Pharmaceuticals?

Xenon Pharmaceuticals (NASDAQ:XENE) and Tyra Biosciences (NASDAQ:TYRA) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Xenon Pharmaceuticals' return on equity of -43.98% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%
Tyra Biosciences	N/A	-46.39%	-43.07%

95.4% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are owned by institutional investors. 2.9% of Xenon Pharmaceuticals shares are owned by insiders. Comparatively, 12.5% of Tyra Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Xenon Pharmaceuticals has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

Xenon Pharmaceuticals presently has a consensus target price of $77.13, suggesting a potential upside of 27.47%. Tyra Biosciences has a consensus target price of $46.90, suggesting a potential upside of 78.60%. Given Tyra Biosciences' higher possible upside, analysts plainly believe Tyra Biosciences is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	N/A	N/A	-$345.91M	-$4.74	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A

In the previous week, Xenon Pharmaceuticals had 3 more articles in the media than Tyra Biosciences. MarketBeat recorded 4 mentions for Xenon Pharmaceuticals and 1 mentions for Tyra Biosciences. Xenon Pharmaceuticals' average media sentiment score of 1.24 beat Tyra Biosciences' score of 0.00 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tyra Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Xenon Pharmaceuticals beats Tyra Biosciences on 8 of the 14 factors compared between the two stocks.

How does Tyra Biosciences compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Tyra Biosciences (NASDAQ:TYRA) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

In the previous week, Kiniksa Pharmaceuticals International and Kiniksa Pharmaceuticals International both had 1 articles in the media. Kiniksa Pharmaceuticals International's average media sentiment score of 1.63 beat Tyra Biosciences' score of 0.00 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Tyra Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kiniksa Pharmaceuticals International presently has a consensus price target of $87.38, indicating a potential upside of 10.72%. Tyra Biosciences has a consensus price target of $46.90, indicating a potential upside of 78.60%. Given Tyra Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Tyra Biosciences is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Kiniksa Pharmaceuticals International has a beta of 0.05, indicating that its share price is 95% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market.

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to Tyra Biosciences' net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%
Tyra Biosciences	N/A	-46.39%	-43.07%

Kiniksa Pharmaceuticals International has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$840.85M	7.32	$59.01M	$0.97	81.36
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A

Summary

Kiniksa Pharmaceuticals International beats Tyra Biosciences on 9 of the 15 factors compared between the two stocks.

How does Tyra Biosciences compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and Tyra Biosciences (NASDAQ:TYRA) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

PTC Therapeutics presently has a consensus target price of $98.55, indicating a potential upside of 39.53%. Tyra Biosciences has a consensus target price of $46.90, indicating a potential upside of 78.60%. Given Tyra Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Tyra Biosciences is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

84.1% of Tyra Biosciences shares are held by institutional investors. 5.3% of PTC Therapeutics shares are held by company insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

PTC Therapeutics has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market.

PTC Therapeutics has higher revenue and earnings than Tyra Biosciences. PTC Therapeutics is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.41	$682.64M	-$0.58	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A

Tyra Biosciences has a net margin of 0.00% compared to PTC Therapeutics' net margin of -3.80%. Tyra Biosciences' return on equity of -46.39% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-3.80%	-362.45%	-1.32%
Tyra Biosciences	N/A	-46.39%	-43.07%

In the previous week, PTC Therapeutics had 16 more articles in the media than Tyra Biosciences. MarketBeat recorded 17 mentions for PTC Therapeutics and 1 mentions for Tyra Biosciences. PTC Therapeutics' average media sentiment score of 0.70 beat Tyra Biosciences' score of 0.00 indicating that PTC Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	10 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tyra Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Tyra Biosciences beats PTC Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Tyra Biosciences compare to Ligand Pharmaceuticals?

Tyra Biosciences (NASDAQ:TYRA) and Ligand Pharmaceuticals (NASDAQ:LGND) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Tyra Biosciences presently has a consensus price target of $46.90, suggesting a potential upside of 78.60%. Ligand Pharmaceuticals has a consensus price target of $335.75, suggesting a potential upside of 18.41%. Given Tyra Biosciences' higher probable upside, equities research analysts plainly believe Tyra Biosciences is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00

Tyra Biosciences has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

Ligand Pharmaceuticals has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A
Ligand Pharmaceuticals	$268.09M	21.09	$124.45M	$9.35	30.33

Ligand Pharmaceuticals has a net margin of 67.88% compared to Tyra Biosciences' net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 20.06% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-46.39%	-43.07%
Ligand Pharmaceuticals	67.88%	20.06%	11.68%

84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 12.5% of Tyra Biosciences shares are owned by company insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Ligand Pharmaceuticals had 3 more articles in the media than Tyra Biosciences. MarketBeat recorded 4 mentions for Ligand Pharmaceuticals and 1 mentions for Tyra Biosciences. Ligand Pharmaceuticals' average media sentiment score of 0.33 beat Tyra Biosciences' score of 0.00 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ligand Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ligand Pharmaceuticals beats Tyra Biosciences on 12 of the 16 factors compared between the two stocks.

How does Tyra Biosciences compare to Travere Therapeutics?

Tyra Biosciences (NASDAQ:TYRA) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

Travere Therapeutics has higher revenue and earnings than Tyra Biosciences. Travere Therapeutics is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A
Travere Therapeutics	$591.33M	10.42	-$25.55M	-$0.46	N/A

Tyra Biosciences currently has a consensus target price of $46.90, suggesting a potential upside of 78.60%. Travere Therapeutics has a consensus target price of $61.67, suggesting a potential downside of 5.67%. Given Tyra Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Tyra Biosciences is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Tyra Biosciences has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

In the previous week, Travere Therapeutics had 9 more articles in the media than Tyra Biosciences. MarketBeat recorded 10 mentions for Travere Therapeutics and 1 mentions for Tyra Biosciences. Travere Therapeutics' average media sentiment score of 1.14 beat Tyra Biosciences' score of 0.00 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Travere Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tyra Biosciences has a net margin of 0.00% compared to Travere Therapeutics' net margin of -7.35%. Tyra Biosciences' return on equity of -46.39% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-46.39%	-43.07%
Travere Therapeutics	-7.35%	-55.15%	-6.88%

84.1% of Tyra Biosciences shares are owned by institutional investors. 12.5% of Tyra Biosciences shares are owned by company insiders. Comparatively, 4.4% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Tyra Biosciences beats Travere Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Tyra Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TYRA vs. The Competition

Export

Metric	Tyra Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.57B	$3.99B	$7.28B	$12.72B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-10.94	11.76	271.35	24.06
Price / Sales	N/A	1,302.10	605.78	77.99
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	5.40	17.24	11.18	6.39
Net Income	-$119.95M	-$22.72M	$3.46B	$348.39M
7 Day Performance	0.15%	2.86%	1.95%	1.06%
1 Month Performance	-14.27%	9.66%	7.28%	5.22%
1 Year Performance	124.25%	54.43%	24.58%	16.09%

Tyra Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TYRA Tyra Biosciences	1.9694 of 5 stars	$26.26 +0.8%	$46.90 +78.6%	+122.5%	$1.57B	N/A	N/A	20
XENE Xenon Pharmaceuticals	3.3904 of 5 stars	$63.18 +1.3%	$77.13 +22.1%	+56.5%	$6.03B	$7.50M	N/A	210	Positive News
KNSA Kiniksa Pharmaceuticals International	3.9809 of 5 stars	$79.49 +0.4%	$87.38 +9.9%	+134.2%	$5.99B	$677.56M	81.95	220	Positive News
PTCT PTC Therapeutics	3.6051 of 5 stars	$72.63 -0.3%	$98.55 +35.7%	+38.1%	$5.98B	$1.73B	N/A	1,410	Analyst Downgrade Insider Trade
LGND Ligand Pharmaceuticals	3.8265 of 5 stars	$287.59 -1.4%	$335.75 +16.7%	+80.0%	$5.87B	$268.09M	30.76	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TYRA) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tyra Biosciences (TYRA) Competitors

TYRA vs. XENE, KNSA, PTCT, LGND, and TVTX

How does Tyra Biosciences compare to Xenon Pharmaceuticals?

Summary

How does Tyra Biosciences compare to Kiniksa Pharmaceuticals International?

Summary

How does Tyra Biosciences compare to PTC Therapeutics?

Summary

How does Tyra Biosciences compare to Ligand Pharmaceuticals?

Summary

How does Tyra Biosciences compare to Travere Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA vs. The Competition

Tyra Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tyra Biosciences (TYRA) Competitors

TYRA vs. XENE, KNSA, PTCT, LGND, and TVTX

How does Tyra Biosciences compare to Xenon Pharmaceuticals?

Is XENE or TYRA more profitable?

Do insiders & institutionals hold more shares of XENE or TYRA?

Which has more volatility and risk, XENE or TYRA?

Do analysts recommend XENE or TYRA?

Which has preferable valuation and earnings, XENE or TYRA?

Does the media refer more to XENE or TYRA?

Summary

How does Tyra Biosciences compare to Kiniksa Pharmaceuticals International?

Does the media favor KNSA or TYRA?

Do analysts recommend KNSA or TYRA?

Do insiders & institutionals hold more shares of KNSA or TYRA?

Which has more risk & volatility, KNSA or TYRA?

Is KNSA or TYRA more profitable?

Which has better valuation and earnings, KNSA or TYRA?

Summary

How does Tyra Biosciences compare to PTC Therapeutics?

Do analysts rate PTCT or TYRA?

Do institutionals & insiders believe in PTCT or TYRA?

Which has more volatility and risk, PTCT or TYRA?

Which has better valuation & earnings, PTCT or TYRA?

Is PTCT or TYRA more profitable?

Does the media favor PTCT or TYRA?

Summary

How does Tyra Biosciences compare to Ligand Pharmaceuticals?

Do analysts rate TYRA or LGND?

Which has more volatility & risk, TYRA or LGND?

Which has higher valuation and earnings, TYRA or LGND?

Is TYRA or LGND more profitable?

Do insiders & institutionals hold more shares of TYRA or LGND?

Does the media refer more to TYRA or LGND?

Summary

How does Tyra Biosciences compare to Travere Therapeutics?

Which has higher earnings and valuation, TYRA or TVTX?

Do analysts rate TYRA or TVTX?

Which has more risk & volatility, TYRA or TVTX?

Does the media favor TYRA or TVTX?

Is TYRA or TVTX more profitable?

Do insiders and institutionals have more ownership in TYRA or TVTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA vs. The Competition

Tyra Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools